Bafna Pharmaceuticals (BAFNAPH) Q3 2026 earnings summary

Executive summary

• Revenue from operations for the quarter ended 31st December 2025 was INR 3,828.58 lakhs, up from INR 3,318.76 lakhs in the same quarter last year.

• Profit before tax for the quarter was INR 183.69 lakhs, compared to INR 94.77 lakhs in the same quarter last year.

• The financial results were reviewed by the Audit Committee and approved by the Board on 11th February 2026.

Financial highlights

• Total income for the quarter was INR 3,950.52 lakhs, up from INR 3,337.72 lakhs year-over-year.

• Total expenses for the quarter were INR 3,766.83 lakhs, compared to INR 3,241.75 lakhs in the prior year quarter.

• Earnings per share (basic and diluted) for the quarter were INR 0.78, up from INR 0.40 year-over-year.

• For the nine months ended 31st December 2025, total income was INR 11,137.27 lakhs and profit before tax was INR 835.06 lakhs.

Key financial ratios and metrics

• Gross margin improved as revenue growth outpaced the increase in cost of materials consumed.

• Finance costs for the quarter were INR 86.24 lakhs, up from INR 63.54 lakhs year-over-year.